Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of Revenue by Reportable Segment

The following table presents our revenues disaggregated by transaction type (see Note 13 - Segment Information for our revenues disaggregated by segment):

	Three Months Ended March 31,
Revenues by transaction type	2024		2023
Subscription revenues	$	403.1	$	393.2
Re-occurring revenues	102.5		107.7
Transactional and other revenues	115.6		128.2
Revenues	$	621.2	$	629.1

The following table summarizes revenues by reportable segment for the periods indicated:

	Three Months Ended March 31,
	2024		2023
Academia & Government	317.7		314.7
Intellectual Property	200.9		209.1
Life Sciences & Healthcare	102.6		105.3
Total Revenues	$	621.2	$	629.1

Schedule of Segment Reporting Information, by Segment

The following table presents segment profitability and a reconciliation to Net income (loss) attributable to ordinary shares for the periods indicated:

	Three Months Ended March 31,
	2024		2023
Academia & Government	123.5		125.4
Intellectual Property	83.1		94.6
Life Sciences & Healthcare	29.7		32.7
Total Adjusted EBITDA	$	236.3	$	252.7
Provision (benefit) for income taxes	(15.0)		63.6
Depreciation and amortization	(179.4)		(172.6)
Interest expense, net	(70.2)		(73.6)
Transaction related costs	(4.4)		(1.7)
Share-based compensation expense	(15.4)		(41.2)
Restructuring and other impairments	(9.5)		(9.4)
Fair value adjustment of warrants	5.2		(1.1)
Other(1)	(22.6)		26.8
Net income (loss)	(75.0)		43.5
Dividends on preferred shares	(18.8)		(18.8)
Net income (loss) attributable to ordinary shares	$	(93.8)	$	24.7
(1) Primarily reflects the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance. The three months ended March 31, 2024 also includes a $15.8 loss on the divestiture discussed in Note 2 - Acquisitions and Divestitures. The three months ended March 31, 2023 also includes a $49.4 gain on legal settlement. Refer to Note 10 - Other Operating Expense (Income), Net and Note 14 - Commitments and Contingencies for further information.